organ growth neotract momentum keep us recommend name
morn report result beat consensu top- bottom-
line organ constant currenc sale growth day-adjust ep
manag attribut sequenti organ sale growth quarter
solid volum new product contribut price furthermor compani key
acquisit neotract deliv sale y/i easili top
target manag stuck growth target busi
view overli conserv take model bogey lastli
manag announc restructur initi implement gener
annual save contribut begin mid-singl
digit organ growth still expect continu momentum neotract margin
like lift come year suggest start build posit name
cc guidanc maintain morn report result
sale ahead street estim
organ constant currenc revenu growth exclud impact one fewer ship
day aid normal distributor purchas
ep beat consensu estim due favor fx
tax lower opex manag re-affirmed guid constant currenc revenu
growth organ growth outlook report revenu
growth increas midpoint due fx ep full year
rais cent growth
point call call earlier today three key takeaway
us first organ sale growth area signific investor concern
head print acceler sequenti growth aid
normal distributor purchas enter well strong contribut
new product solid price manag still expect organ growth
includ neotract continu momentum core busi
second year-over-year growth exhibit neotract doubl
estim manag cite increas payer coverag clinic benefit
urolift key driver expect drive acceler throughout year
lastli manag announc call restructur initi gener
save look drive annual save
stock thought share trade healthi multipl time
ep target peer around howev given strength neotract
oper leverag avail buoy restructur announc
believ profit estim continu rise push share even
higher consequ recommend investor start build posit
failur realiz margin expans product recal competit
global diversifi medic technolog product provid
price close may
ep estim
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
sourc compani report piper jaffray co estim
page
good expens net incom analysi gross analysi vascular north north north north north inc
thousand except per share data
good sold
good sold
percent sale
good sold
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
